HFS
VRTX icon

Hopwood Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Hopwood Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$3.52K – 295
2025
Q3 		$3.52K Hold
9
– – ﹤0.01% 289
2025
Q2 		$4.01K Hold
9
– – ﹤0.01% 264
2025
Q1 		$4.36K Hold
9
– – ﹤0.01% 271
2024
Q4 		$3.63K Buy
+9
New +$4.17K ﹤0.01% 281

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Hopwood Financial Services's VRTX Position: Q4 2025 in Review

Hopwood Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 9 shares — an estimated $3.52K sold.

Hopwood Financial Services first reported a position in VRTX in Q4 2024 and held it in 4 quarters. The position peaked at $4.36K in Q1 2025. 1,674 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Hopwood Financial Services reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hopwood Financial Services sold 9 Vertex Pharmaceuticals shares in Q4 2025, an estimated $3.52K.
  • Hopwood Financial Services first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Hopwood Financial Services's Vertex Pharmaceuticals position peaked at $4.36K in Q1 2025.
  • 1,674 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Hopwood Financial Services's 13F filing for Q4 2025, filed 16 Jan 2026.